Mediwound (NASDAQ:MDWD) is scheduled to post its quarterly earnings results before the market opens on Tuesday, November 13th. Analysts expect Mediwound to post earnings of ($0.19) per share for the quarter.

Shares of NASDAQ MDWD opened at $5.65 on Friday. The company has a market capitalization of $156.61 million, a P/E ratio of -9.11 and a beta of -0.03. Mediwound has a 52 week low of $3.56 and a 52 week high of $7.35.

Several equities research analysts recently commented on the company. Oppenheimer set a $14.00 price target on Mediwound and gave the company a “buy” rating in a research note on Tuesday, August 7th. Wells Fargo & Co set a $11.00 target price on Mediwound and gave the stock a “buy” rating in a report on Tuesday, September 25th. ValuEngine upgraded Mediwound from a “hold” rating to a “buy” rating in a report on Tuesday, October 2nd. Finally, Zacks Investment Research upgraded Mediwound from a “sell” rating to a “hold” rating in a report on Thursday, October 25th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $11.33.

TRADEMARK VIOLATION WARNING: “Mediwound (MDWD) Scheduled to Post Earnings on Tuesday” was first published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this article on another domain, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The correct version of this article can be read at

Mediwound Company Profile

MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products to address unmet needs. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns in the European Union, Israel, and Argentina.

Recommended Story: Asset Allocation

Earnings History for Mediwound (NASDAQ:MDWD)

Receive News & Ratings for Mediwound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mediwound and related companies with's FREE daily email newsletter.